Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

August 11, 2023
Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-termMizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term
Share This

Jared Holz, Mizuho healthcare strategist, joins ‘Squawk Box’ to discuss Novo Nordisk’s quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.

Latest Mizuho News

Mizuho’s Jared Holz on Moderna’s leg up on new cancer shot data

Mizuho’s Jared Holz on Moderna’s leg up on new cancer shot data

August 19, 2026
Nvidia holders to focus on AI data, Mizuho's Rakesh says

Nvidia holders to focus on AI data, Mizuho's Rakesh says

August 26, 2026
Mizuho Retains “Outstanding” Community Reinvestment Act Ratings

Mizuho Retains “Outstanding” Community Reinvestment Act Ratings

August 10, 2026

Mizuho news from around the globe

back-to-top-blue